Brookwood Investment Group LLC Invests $681,000 in Gilead Sciences, Inc. $GILD

Brookwood Investment Group LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 6,136 shares of the biopharmaceutical company’s stock, valued at approximately $681,000.

Several other large investors have also added to or reduced their stakes in GILD. Norges Bank bought a new stake in Gilead Sciences during the 2nd quarter worth about $2,150,268,000. Ameriprise Financial Inc. raised its holdings in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after acquiring an additional 5,392,191 shares in the last quarter. Invesco Ltd. boosted its position in Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in Gilead Sciences by 164.4% in the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after purchasing an additional 2,169,266 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $238,083,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.9%

Shares of GILD opened at $121.60 on Friday. The firm has a market cap of $150.87 billion, a P/E ratio of 18.85, a price-to-earnings-growth ratio of 0.65 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a 52 week low of $88.57 and a 52 week high of $128.70. The firm’s 50-day simple moving average is $123.05 and its 200 day simple moving average is $117.11.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the business posted $2.02 earnings per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the transaction, the chief financial officer owned 153,503 shares in the company, valued at $18,727,366. This trade represents a 1.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 136,257 shares of company stock worth $16,855,192. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on GILD. Needham & Company LLC increased their price objective on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. Citigroup boosted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Sanford C. Bernstein set a $135.00 target price on shares of Gilead Sciences and gave the company an “outperform” rating in a research note on Monday, December 29th. Finally, HSBC lifted their price target on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $131.68.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.